Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

ABC: Highly active and entirely calcineurin and m-TOR inhibitor-free gvhd prevention regimen

View Full Paper
Ask AI
Bookmark
Share

Authors

SBStéphanie BoisclairKCKelli ColeFMFarzaneh Mashayekhi

Discussion

Loading...

Member takes

Overview

Phase I-IIb trial demonstrates enhanced outcomes in graft-versus-host disease prevention using abatacept in hematologic malignancies.

Key Points

  • To evaluate the efficacy of an entirely calcineurin and m-TOR inhibitor-free regimen for GvHD prophylaxis.
  • Conducted a phase I-IIb trial with patients having hematologic malignancies undergoing peripheral blood BMT.
  • Utilized a combination of cyclophosphamide, bortezomib, and abatacept for GvHD prevention.
  • Assessed engraftment, survival, and GvHD incidences in matched and unmatched donor cohorts.
  • 54 patients enrolled with a median follow-up of 8.7 months.
  • Estimated 1-year overall survival was 92.1% and relapse-free survival was 72.6%.
  • Cumulative incidences of grades II-IV acute and moderate to severe chronic GvHD were 9.3% and 14.3%, respectively.

Cite This Study

Boisclair et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1a1https://doi.org/10.1182/blood-2025-2469
View Full Paper
Ask AI
Bookmark
Share